Sumanta K Pal

Summary

Affiliation: City of Hope National Medical Center
Country: USA

Publications

  1. doi request reprint Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Breast Cancer Res Treat 119:25-32. 2010
  2. pmc Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA Electronic address
    Urol Oncol 31:1826-31. 2013
  3. pmc A new age for vaccine therapy in renal cell carcinoma
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Cancer J 19:365-70. 2013
  4. ncbi request reprint Optimizing systemic therapy for bladder cancer
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    J Natl Compr Canc Netw 11:793-804. 2013
  5. doi request reprint Differentiating mTOR inhibitors in renal cell carcinoma
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, Division of Genitourinary Malignancies, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
    Cancer Treat Rev 39:709-19. 2013
  6. pmc Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, United States of America
    PLoS ONE 8:e63341. 2013
  7. ncbi request reprint Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma
    Sumanta Kumar Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    Clin Adv Hematol Oncol 11:146-55. 2013
  8. pmc Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
    Clin Genitourin Cancer 11:121-7. 2013
  9. pmc Enzalutamide for the treatment of prostate cancer
    Sumanta K Pal
    City of Hope Comprehensive Cancer Center, Department of Medical Oncology and Experimental Therapeutics, 1500 East Duarte Road, Duarte, CA 91010, USA
    Expert Opin Pharmacother 14:679-85. 2013
  10. pmc Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer
    Sumanta K Pal
    Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
    BMC Cancer 12:435. 2012

Collaborators

Detail Information

Publications49

  1. doi request reprint Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Breast Cancer Res Treat 119:25-32. 2010
    ..These trial results pose legitimate questions regarding the future application of anthracyclines in the adjuvant breast cancer setting...
  2. pmc Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA Electronic address
    Urol Oncol 31:1826-31. 2013
    ..We seek to define outcomes associated with systemic therapy (including immunotherapy, cytotoxic therapy, and targeted agents) for sarcomatoid mRCC, with attention to novel prognostic schema...
  3. pmc A new age for vaccine therapy in renal cell carcinoma
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Cancer J 19:365-70. 2013
    ..Herein, the current status of vaccine-based therapies for mRCC is described in detail. Furthermore, challenges to clinical implementation (eg, cost, optimal pairing with targeted agents, appropriate sequencing) are presented. ..
  4. ncbi request reprint Optimizing systemic therapy for bladder cancer
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    J Natl Compr Canc Netw 11:793-804. 2013
    ....
  5. doi request reprint Differentiating mTOR inhibitors in renal cell carcinoma
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, Division of Genitourinary Malignancies, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
    Cancer Treat Rev 39:709-19. 2013
    ..Clinical trials of mTOR inhibitors in a variety of tumor types are ongoing, and the role of mTOR inhibitors continues to evolve across the RCC treatment landscape...
  6. pmc Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, United States of America
    PLoS ONE 8:e63341. 2013
    ..We sought to determine whether survival has improved for patients with mRCC diagnosed in the era of targeted therapies, as compared to the era of immunotherapy...
  7. ncbi request reprint Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma
    Sumanta Kumar Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    Clin Adv Hematol Oncol 11:146-55. 2013
    ..Whether results of these studies will lead to a paradigm shift in treatment recommendations for patients with mRCC remains to be determined...
  8. pmc Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
    Clin Genitourin Cancer 11:121-7. 2013
    ..Herein we attempt to characterize the QOL in long-term survivors who received high-dose paclitaxel, etoposide, carboplatin, and ifosfamide (TECTIC)...
  9. pmc Enzalutamide for the treatment of prostate cancer
    Sumanta K Pal
    City of Hope Comprehensive Cancer Center, Department of Medical Oncology and Experimental Therapeutics, 1500 East Duarte Road, Duarte, CA 91010, USA
    Expert Opin Pharmacother 14:679-85. 2013
    ..Enzalutamide, a potent antiandrogen that blocks nuclear translocation of the androgen receptor (AR), is the most recently approved of these agents...
  10. pmc Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer
    Sumanta K Pal
    Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
    BMC Cancer 12:435. 2012
    ..In the setting of de novo MBC, large registry analyses cite positive temporal trends in survival, but the extent to which advances in systemic therapy have contributed to these gains is not clear...
  11. doi request reprint Tivozanib: current status and future directions in the treatment of solid tumors
    Sumanta K Pal
    City of Hope Comprehensive Cancer Center, Department of Medical Oncology and Experimental Therapeutics, 1500 East Duarte Road, Duarte, CA 91010, USA
    Expert Opin Investig Drugs 21:1851-9. 2012
    ..Tivozanib is a novel tyrosine kinase inhibitor (TKI) which inhibits vascular endothelial growth factor (VEGF) receptors-1, -2, and -3 at nanomolar concentrations...
  12. pmc Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
    Clin Genitourin Cancer 10:246-50. 2012
    ..We sought to compare clinical outcomes in patients treated for MIBC with neoadjuvant CG and MVAC at our institution...
  13. pmc Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm
    Sumanta Kumar Pal
    Division of Genitourinary Oncology, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Mol Cancer Ther 11:526-37. 2012
    ..Although VEGF and mTOR inhibition have dramatically improved outcomes for patients with mRCCs, a surge above the current plateau with these agents will likely require exploring new avenues...
  14. pmc Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma
    Sumanta Kumar Pal
    Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA
    Target Oncol 6:5-16. 2011
    ..The application of mTOR inhibitors in unique populations is also described...
  15. pmc Triple negative breast cancer: unmet medical needs
    Sumanta Kumar Pal
    Department of Medical Oncology and Experimental Therapeutics, Division of Genitourinary Malignancies, City of Hope Comprehensive Cancer Center, 1500 Duarte Road, Duarte, CA, USA
    Breast Cancer Res Treat 125:627-36. 2011
    ..The clinical characteristics of TNBC and clinical experience to date with novel targeted agents under development for this aggressive phenotype is reviewed...
  16. pmc Critical appraisal of cabazitaxel in the management of advanced prostate cancer
    Sumanta Kumar Pal
    Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA
    Clin Interv Aging 5:395-402. 2010
    ..This review describes in detail the preclinical and clinical development of cabazitaxel...
  17. pmc Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers
    Sumanta Kumar Pal
    Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Mol Cancer Ther 9:3115-25. 2010
    ..Herein, the clinical relevance of putative RCC biomarkers is examined in detail...
  18. pmc Akt inhibitors in clinical development for the treatment of cancer
    Sumanta Kumar Pal
    City of Hope Comprehensive Cancer Center, Department of Medical Oncology and Experimental Therapeutics, 1500 East Duarte Road, Duarte, CA 91010, USA
    Expert Opin Investig Drugs 19:1355-66. 2010
    ..More recently, several agents have been developed that antagonize Akt--these agents are in various stages of clinical testing...
  19. ncbi request reprint Renal cell carcinoma therapy in 2010: many options with little comparative data
    Sumanta Kumar Pal
    Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    Clin Adv Hematol Oncol 8:191-200. 2010
    ..Finally, available cost-effectiveness data for targeted therapies in mRCC are presented. The amalgam of these studies may offer the oncologist greater clarity in clinical decision-making...
  20. doi request reprint Adjuvant systemic therapy for older adults with early-stage breast cancer
    Sumanta Kumar Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Womens Health (Lond Engl) 5:251-62. 2009
    ..Clinical tools such as the geriatric assessment and biologic assays, such as the 21-gene recurrence score, may ultimately play a role in treatment algorithms for this unique demographic...
  21. doi request reprint Triple-negative breast cancer: novel therapies and new directions
    Sumanta Kumar Pal
    Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Maturitas 63:269-74. 2009
    ..Finally, preclinical studies provide a signal of potential activity with use of heat shock protein 90 (Hsp90) and Src inhibitors in this breast cancer subtype...
  22. doi request reprint Adjuvant chemotherapy for older adults with breast cancer: making the standard a standard
    Sumanta Kumar Pal
    Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Womens Health (Lond Engl) 5:481-4. 2009
    ..The current review explores both the implications and potential caveats of this innovative trial. CALGB 49907 represents a paradigm for further studies of adjuvant cancer therapy in older adults...
  23. doi request reprint Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways
    Sumanta Kumar Pal
    Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, United States
    Maturitas 64:61-6. 2009
    ..On the basis of these compelling data, both abiraterone and MDV3100 will be examined in the phase III setting...
  24. pmc Papillary carcinoma of the breast: an overview
    Sumanta Kumar Pal
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Breast Cancer Res Treat 122:637-45. 2010
    ..The scarcity of information underscores the need for further treatment- and outcome-related studies in papillary carcinoma of the breast...
  25. pmc Targeted therapies for non-small cell lung cancer: an evolving landscape
    Sumanta Kumar Pal
    Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA
    Mol Cancer Ther 9:1931-44. 2010
    ..Herein, the clinical development of novel therapies for NSCLC is described, including some discussion of relevant biomarkers and determination of synergy with both cytotoxic therapy and other targeted agents...
  26. doi request reprint Targeted therapies for renal cell carcinoma: understanding their impact on survival
    Sumanta Kumar Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Target Oncol 5:131-8. 2010
    ..Ultimately, head-to-head trials comparing targeted therapies are necessary to resolve clinical equipoise. Several ongoing efforts juxtaposing the approved agents for mRCC are discussed...
  27. pmc Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer
    Wang Zhang
    Department of Cancer Immunotherapy and Immunology, City of Hope Comprehensive Cancer Center, Duarte, California, United States of America
    PLoS ONE 8:e65121. 2013
    ..This study aimed to understand the role of myeloid cell clusters in uninvolved regional lymph nodes from early stage non-small cell lung cancer patients...
  28. doi request reprint A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis
    Rebecca A Nelson
    Division of Biostatistics, Department of Information Science, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Clin Genitourin Cancer 11:303-10. 2013
    ..We sought to confirm these trends through exploration of the Surveillance, Epidemiology and End Results (SEER) registry...
  29. doi request reprint Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer
    Bertram E Yuh
    Division of Urology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    J Urol 189:1682-6. 2013
    ..In this review we summarize the efficacy of neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer based on currently published studies...
  30. pmc Preoperative therapy for localized prostate cancer: a comprehensive overview
    Jensen Hu
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Maturitas 74:3-9. 2013
    ..Of these, 55 possessed a number of patients (i.e., greater than 10) deemed worth of the current analysis. Beyond outlining these datasets, we discuss the relevance of clinical and pathologic endpoints in assessing preoperative therapy...
  31. doi request reprint Systemic therapies for metastatic renal cell carcinoma in older adults
    Sumanta K Pal
    Division of Genitourinary Malignancies, Department of Medical Oncology Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
    Drugs Aging 28:635-49. 2011
    ..Ultimately, tools such as the Comprehensive Geriatric Assessment (CGA) that account for physiological (as opposed to chronological) age may prove useful in the evaluation and treatment of older adults with mRCC...
  32. pmc Management of docetaxel failures in metastatic castrate-resistant prostate cancer
    Sumanta K Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Urol Clin North Am 39:583-91. 2012
    ..This article details the efficacy and safety of these agents to provide a framework for their clinical use...
  33. doi request reprint Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status
    Arash Naeim
    Division of Hematology Oncology, University of California, Los Angeles, CA 90095, USA
    Clin Breast Cancer 10:136-43. 2010
    ..The goal of the current study is to understand the effect of patient age and health status on oncologists' decision to recommend adjuvant treatment (endocrine therapy and chemotherapy) in older women with HR-positive breast cancer...
  34. pmc S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites
    Jiehui Deng
    Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute and City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Cancer Cell 21:642-54. 2012
    ..Analyzing tumor-free lymph nodes from cancer patients shows elevated myeloid infiltrates, STAT3 activity, and increased survival signal...
  35. ncbi request reprint Lessons learned from the bevacizumab experience
    Joanne Mortimer
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Cancer Control 19:309-16. 2012
    ..It has been approved in the management of metastatic colorectal cancer, non-small cell lung cancer, renal cancers, and recurrent glioblastoma multiforme...
  36. doi request reprint Safety considerations for use of bone-targeted agents in patients with cancer
    Joanne E Mortimer
    City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Semin Oncol 37:S66-72. 2010
    ....
  37. doi request reprint Management of non-small-cell lung cancer in the older adult
    Ari VanderWalde
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Maturitas 68:311-21. 2011
    ..This article serves as a review of the available evidence in the evaluation, treatment, and support of the older adult with cancer...
  38. doi request reprint Targeting angiopoietin-2 signaling in cancer therapy
    Zeynep Eroglu
    City of Hope Comprehensive Cancer Center, Department of Medical Oncology and Experimental Therapeutics, 1500 East Duarte Road, Duarte, CA 91010, USA
    Expert Opin Investig Drugs 22:813-25. 2013
    ..e., with small molecules such as sunitinib or sorafenib). While these agents do appear to delay cancer progression in the clinic, they are not curative approaches...
  39. ncbi request reprint Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma
    Courtney Carmichael
    City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Clin Adv Hematol Oncol 10:307-14. 2012
    ..This article describes the preclinical and clinical evolution of axitinib, with an emphasis on its development and role in mRCC...
  40. ncbi request reprint HER2 targeted therapy in breast cancer...beyond Herceptin
    Sumanta Kumar Pal
    111 934 Factor Building, UCLA Center for the Health Sciences, UCLA Campus Mail Code 167817, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Rev Endocr Metab Disord 8:269-77. 2007
    ....
  41. ncbi request reprint Role of surgery for locally advanced and metastatic renal cell carcinoma
    Robert Torrey
    Division of Urology Urologic Oncology, City of Hope Cancer Center, Duarte, California, USA
    J Natl Compr Canc Netw 9:985-93. 2011
    ..Individualization of care in the setting of a sound oncologic framework may optimize the risk/benefit ratio within individual patient cohorts...
  42. pmc Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis
    Xiwei Wu
    Department of Molecular Medicine, City of Hope National Medical Center and Beckman Research Institute, Duarte, California, United States of America
    PLoS ONE 7:e35661. 2012
    ..The 4-miRNA is associated with ccRCC metastasis and prognosis. The signature is ready for and will benefit from further large clinical cohort validation and has the potential for clinical application...
  43. ncbi request reprint Targeting HER2 Epitopes
    Sumanta Kumar Pal
    Division of Hematology Oncology, Department of Medicine, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA
    Semin Oncol 33:386-91. 2006
    ..Recent data suggest a synergistic interaction of HER2 epitope-targeting agents when used in combination...
  44. doi request reprint The role of targeting mammalian target of rapamycin in lung cancer
    Sumanta Kumar Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Clin Lung Cancer 9:340-5. 2008
    ..Herein, we explore the relationship of mTOR to lung carcinogenesis and further describe clinical trials of mTOR inhibitors alone and in combination with chemotherapeutic and targeted agents...
  45. doi request reprint Impact of age, sex, and comorbidity on cancer therapy and disease progression
    Sumanta Kumar Pal
    Experimental Therapeutics and Cancer Control and Population Sciences Program, Cancer and Aging Research Program, City of Hope Comprehensive Cancer Center, 1500 E Duarte Rd, Duarte, CA, USA
    J Clin Oncol 28:4086-93. 2010
    ..Taken together, age, sex, and comorbidity each encompass a complex array of physiologic and molecular variations that may each aid in personalizing care for the patient with cancer...
  46. doi request reprint Novel tyrosine kinase inhibitors for renal cell carcinoma
    Tanya B Dorff
    Department of Medicine, USC Keck School of Medicine, USC Norris Comprehensive Cancer Center, 1441 Eastlake Ave 3440, Los Angeles, CA 90033, USA
    Expert Rev Clin Pharmacol 7:67-73. 2014
    ..New pathways being targeted include FGF, angiopoietin and MET. In this review, we highlight five novel tyrosine kinase inhibitors in development for RCC: tivozanib; dovitinib; regorafenib; cabozantinib; and tivantinib. ..
  47. doi request reprint Evaluating the older patient with cancer: understanding frailty and the geriatric assessment
    Sumanta Kumar Pal
    Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    CA Cancer J Clin 60:120-32. 2010
    ..This review describes key studies from the geriatric literature that provide principles for assessing health status in the older patient, and ways that these principles can be applied to oncology care in an older population are proposed...
  48. ncbi request reprint Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy
    Sumanta Kumar Pal
    UCLA Center for the Health Sciences, Los Angeles, CA 90095, USA
    Anticancer Drugs 16:483-94. 2005
    ....
  49. doi request reprint An association between invasive breast cancer and familial idiopathic hyperparathyroidism: a case series and review of the literature
    Sumanta Kumar Pal
    Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Breast Cancer Res Treat 115:1-5. 2009
    ..We explore genetic and molecular rationales for an association between these metabolic and neoplastic processes...